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NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer
cells via the Akt signalling pathway
Grant D. Stewart1,2*, Jyoti Nanda1, David J.G. Brown1, Antony C.P. Riddick1, James A. Ross2 and Fouad K. Habib1
1Prostate Research Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, Scotland, United Kingdom
2Tissue Injury and Repair Group, Department of Clinical and Surgical Sciences (Surgery),
University of Edinburgh, Edinburgh, Scotland, United Kingdom
Nitric oxide-donating non-steroidal anti-inﬂammatory drugs are
safer than traditional NSAIDs and inhibit the growth of prostate
cancer cells with greater potency than NSAIDs. In vivo, prostate
cancer deposits are found in a hypoxic environment which induces
resistance to chemotherapy. The aim of this study was to assess
the effects and mechanism of action of a NO-NSAID called NO-
sulindac on the PC-3 prostate cancer cell line under hypoxic con-
ditions. NO-sulindac was found to have pro-apoptotic, cytotoxic,
and anti-invasive effect on PC-3 cells under normoxia and hy-
poxia. NO-sulindac was signiﬁcantly more cytotoxic than sulindac
at all oxygen levels. The sulindac/linker and NO-releasing subunits
both contributed to the cytotoxic effects of NO-sulindac. Resist-
ance of PC-3 cells to NO-sulindac was induced as the oxygen con-
centration declined. Hypoxia-induced chemoresistance was
reversed by knocking-down hypoxia-inducible factor-1a (HIF-1a)
mRNA using RNAi. Nuclear HIF-1a levels were upregulated at
0.2% oxygen but reduced by treatment with NO-sulindac, as was
Akt phosphorylation. NO-sulindac treatment of hypoxic PC-3 cells
transfected with a reporter construct, downregulated activation of
the hypoxia response element (HRE) promoter. Co-transfection of
PC-3 cells with the HRE promoter reporter construct and myr-
Akt (constitutively active Akt) plasmids reversed the NO-sulindac
induced reduction in HRE activation. Real-time polymerase chain
reaction analysis of hypoxic, NO-sulindac treated PC-3 cells
showed downregulation of lysyl oxidase and carbonic anhydrase
IX mRNA expression. Collectively, these novel ﬁndings demon-
strate that NO-sulindac directly inhibits the hypoxia response of
PC-3 prostate cancer cells by inhibiting HIF-1a translation via the
Akt signalling pathway. The ability of NO-sulindac to inhibit
tumour adaption to hypoxia has considerable relevance to the
future management of prostate cancer with the same cellular
properties as PC-3.
' 2008 Wiley-Liss, Inc.
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In Western Europe and North America, prostate cancer is the
commonest cancer and the second most common cause of cancer
death in men. In the United Kingdom, prostate cancer accounts for
23% of all new male cancer diagnoses and 13% of male cancer-
related deaths.1
Non-steroidal anti-inﬂammatory drugs (NSAIDs) inhibit
tumourigenesis in a variety of cancers.2–4 In vitro studies have
shown that conventional NSAIDs, at physiological achievable
doses, inhibit the proliferation of immortalised human prostate
cancer cells.5 Additionally, meta-analyses of observational studies
of men taking regular NSAIDs have reported statistically signiﬁ-
cant reductions in risk of prostate cancer.6,7 However, conven-
tional NSAIDs have several side-effects, particularly gastrointesti-
nal bleeding, which limit their use in elderly patients with prostate
cancer. In an attempt to reduce the side-effects of traditional
NSAIDs, cyclooxygenase-2 inhibitors and nitric oxide (NO•)-
donating non-steroidal anti-inﬂammatory drugs (NO-NSAIDs)
have been developed.
NO-NSAIDs consist of a traditional NSAID group to which a
NO-donating group has been covalently attached via an aromatic
or aliphatic spacer.8 The NO• group of NO-NSAIDs confers its
protective effect on the gastric mucosa by increasing mucosal
blood supply and mucous secretion. The increased mucous secre-
tion protects patients from the most serious side effect of NSAIDs,
namely, gastric erosions.9 Therefore, NO-NSAIDs combine the
anti-proliferative effects of NSAIDs with the gastric protec-
tion10,11 and potential tumouricidal effects of NO•.12 Thus, NO-
NSAIDs are potentially powerful agents against malignancy.
Treatment of human pancreatic, prostate, lung, colonic and
tongue carcinoma cell lines with NO-NSAIDs has shown inhibi-
tion of cell proliferation, induction of apoptosis and altered cell
cycle distribution.13 In vivo colorectal cancer models have also
shown an anti-proliferative effect for NO-aspirin.14 Furthermore,
NO-NSAIDs have been demonstrated to have chemopreventative
activity in both colorectal and pancreatic cancer models.15,16
Hypoxia has been demonstrated in many solid human tumours,
including prostate cancer.17–19 Hypoxia is an independent prog-
nostic indicator of poor clinical outcome for patients with prostate
and other cancers.20,21 Hypoxia has also been shown to correlate
with increased tumour invasiveness, metastases and resistance to
some chemotherapy treatments in prostate cancer.20,22–24
The master regulator of oxygen homeostasis is the transcription
factor hypoxia-inducible factor-1 (HIF-1).25 HIF-1, an ab hetero-
dimeric transcription factor, consists of a constitutively expressed
HIF-1b subunit and a hypoxia-inducible HIF-1a subunit. There
are 5 groups of HIF-1 target genes particularly relevant to
tumourigenesis, including angiogenic factors [e.g., vascular endo-
thelial growth factor (VEGF)], glucose transporters, glycolytic
enzymes, survival factors and invasion factors.25 HIF-1 is at the
centre of most adaptive responses of cancer cells to hypoxia and
overexpression of HIF-1a has been associated with increased
patient mortality in several cancer types.25,26 Understanding the
regulation of factors, such as HIF-1a, which modulate the
response of a tumour to hypoxia may be helpful in designing anti-
cancer therapies.
The aims of this study were to: (a) assess, for the ﬁrst time, the
effect of a NO-NSAID called NO-sulindac on the survival and
invasive potential of PC-3 hormone-insensitive prostate cancer
cell line under hypoxic conditions; (b) determine the effect that
NO-sulindac had on the hypoxia response mounted by prostate
tumour cells to low oxygen conditions; and (c) identify possible
mechanisms of action.
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Material and methods
Cell culture and reagents
All chemicals and reagents were purchased from Sigma (Gil-
lingham, UK) unless stated otherxwise. PC-3 cells (obtained from
the European Collection of Cell Cultures, Salisbury, UK) were
cultured in RPMI-1640 medium supplemented with 10% foetal
calf serum, 50 units/ml penicillin, 50 lg/ml streptomycin and 2
mmol glutamine (all Invitrogen, Paisley, UK). Cells were seeded
into 6-well plates at 3 3 105cells/well for all experiments, except
where stated. Hypoxia was induced by incubating PC-3 cells for
48 hr within a humidiﬁed hypoxia incubator at 0.2% oxygen using
a PROOX 110 oxygen controller (BioSpherix, Redﬁeld, NY). NO-
sulindac (NCX 1102), NCX 221 denitrated analogue and sulindac
(Fig. 1) were donated by NicOx (Sophia Antipolis, France) and
prepared in dimethyl sulfoxide (DMSO) with ﬁnal concentrations
of DMSO of 0.1%.
Assessment of cell death
Assessment of cytotoxicity was performed using propidium
iodide (PI) as described previously.27 Apoptosis was assessed
using annexin V/PI staining (all reagents Bender Medsystems,
Vienna, Austria) followed by ﬂow cytometric analysis. After
washing cells in D-PBS, 5 ll annexin V-ﬂuorescein isothiocyanate
(FITC) was added to 195 ll D-PBS diluted cells and incubated in
the dark at room temperature for 10 min. Cells were then washed
and resuspended in 190 ll binding buffer (diluted 1:4 in distilled
water). Ten microlitres of PI (20 lg/ml) was added before ﬂow
cytometric analysis. The emission wavelength of PI was plotted
against the emission wavelength of annexin V-FITC. Early apo-
ptotic cells were annexin V positive, PI negative; late apoptotic/
early necrotic cells were annexin V positive, PI positive; and ne-
crotic cells were annexin V negative, PI positive. Very few cells
(<1%) stained annexin positive/PI negative following NO-sulin-
dac treatment, i.e., were not identiﬁed as dying/dead by PI staining
alone. As such, it was elected to use PI staining alone for determi-
nation of cytotoxic effect in the majority of experiments.
Estimation of nitrite production
Nitrite production, an indicator of the production of nitric oxide,
was measured using the Griess reagent (1% sulfanilamide and
0.1% (N-1-naphthyl)ethylenediamine dihydrochloride) in 2.5% w/
w phosphoric acid. Griess reagent (25 ll) and medium from
treated cells (75 ll) were mixed and incubated for 10 min at room
temperature in a 96-well plate. Absorbance was measured at 540
nm using a MR3000 Dynatech plate reader (Dynex Technologies,
Worthing, UK) and compared to a sodium nitrite standard curve
(concentration range 0.024–50 lM).
Cell cycle analysis
PC-3 cells were harvested as mentioned earlier and resuspended
in 1 ml of nuclear staining solution (NSS) [NSS: 5 mg PI, 100 mg
sodium citrate and 0.3 ml Nonidet P40 (NP40), in 100 ml distilled
water]. One millilitre of 1 mg/ml RNase A solution (diluted with
1.12% sodium citrate) was then added to the PC-3 cells and incu-
bated in the dark at room temperature for 30 min. The DNA con-
tent of the cells was then analysed by ﬂow cytometry.
Assessment of cell invasion
BD BioCoatTM Tumor Invasion System (BD Biosciences, San
Jose, CA) was used to assess cell invasion. PC-3 cells were seeded
at 1 3 104 cells/24 well in RPMI-1640 medium without FCS.
RPMI-1640 medium with 10% FCS was used as the chemoattrac-
tant in the lower chamber. After 24 hr incubation under standard
conditions, the cells were treated as per experimental protocol.
Cell invasion was assessed by measuring the ﬂuorescence of
invading cells labelled with 4 lg/ml Calcein AM (Molecular
Probes, Eugene, OR) in Hank’s Buffered Salt Solution (HBSS;
Invitrogen). Fluorescence of invading cells was determined using
a ﬂuorescent plate reader with bottom reading capabilities at exci-
tation/emission wavelengths of 485/530 nm (Synergy HT multi-
mode microplate reader, BioTek, Winooski, VT).
Western blot analysis
Western blot analysis, using nuclear protein extracts, was per-
formed as described previously.28,29 Equal amounts of nuclear
protein (10 lg) were subjected to SDS-PAGE in 7.5% gels. Pro-
teins were electrophoresed and then transferred to nitrocellulose
membranes. Membranes were blocked, incubated with primary
and secondary antibodies, and subjected to chemiluminescence
detection and autoradiography. b actin mAb (Abcam, Cambridge,
UK) at 1:10,000 was used as a loading control for all western
blots. HIF-1a mAb (BD Transduction Laboratories, Oxford, UK)
was used at 1:250 dilution. An anti-mouse HRP conjugated sec-
ondary antibody (Upstate, Milton Keynes, UK) at 1:5,000 was
used with b actin and HIF-1a mAb. Phospho-Akt (Ser473) mAb
(Invitrogen) was used at 1:1,000 dilution with an anti-rabbit HRP
linked secondary antibody (Cell Signaling Technologies, Danvers,
MA) at 1:2,000.
Immunocytochemical staining
Immunocytochemistry and subsequent ﬂuorescent microscopy
and image capture were performed as previously described.30 PC-
3 cells were grown on coverslips until 60–80% conﬂuent and then
treated as per experimental protocol. Cells were ﬁxed and immu-
nocytochemistry performed. The primary antibodies used at 1:100
in 10% donkey serum were HIF-1a (Santa Cruz Biotechnology,
Santa Cruz, CA) and ﬁbrillarin (Cytoskeleton, Denver, CO). The
FITC- and Texas red-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA) were used at a
dilution of 1:200 in 1.5% donkey serum, cells were mounted using
Vectashield (Vector Laboratories, Peterborough, UK) containing
1.5 lg/ml 40,60-diamido-2-phenylindole (DAPI) and cells analysed
using ﬂuorescent microscopy. Fluorescent microscopy was per-
formed with a Zeiss Axioplan microscope with a 633 Plan Neo-
ﬂuor objective (Carl Zeiss, Welwyn Garden City, UK) and a
Chroma 83000 ﬁlter set (Chroma Technology Corp., Rockingham,
FIGURE 1 – Chemical structures of traditional sulindac, its NO-derivative (NO-sulindac (NCX 1102)), and the denitrated analogue of
NO-sulindac (NCX 221).
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VT). Each channel was recorded independently, and pseudocolour
images were superimposed. Images were captured with single
emission ﬁlters and analysed using IPLab Spectrum 3.6 (Scana-
lytics Corp., Fairfax, VA).
Luciferase assays
Transient transfections with the pGL2-Tk-HRE promoter re-
porter construct (Dr. G Melillo, Frederick, MD) were performed
using Fugene reagent (Roche Applied Science, Lewes, UK) at a
ratio of 3 ll Fugene per 1 lg plasmid DNA. PC-3 cells were
plated out in 6-well plates (2.5 3 105 cells/well) and transfected
after 24 hr. Cells transfected with 0.5 lg were co-transfected
with 0.5 lg of the reporter construct. Forty-eight hours after
transfection, the cells underwent drug treatment 6 hypoxia. Af-
ter a further 48 hr, the cells were lysed using reporter lysis
buffer (Promega). To quantify luciferase activity, 20 ll lysate
was combined with 20 ll luciferase assay reagent (Promega)
and the resulting light emission measured immediately using a
luminometer (Fluoroskan Ascent FL, Thermo Electron, Basing-
stoke, UK). To measure b-galactosidase activity, 50 ll cell
lysate was combined with 50 ll b-galactosidase assay 2X buffer
(Promega). Following incubation at 37C for 3 hr and stopping
the reaction with 150 ll 1 M sodium carbonate, the absorbance
of the samples was read at 420 nm using a MR3000 Dynatech
plate reader.
RNA extraction and reverse transcription
RNA extraction was performed as previously described.27,31
One microgram of total RNA was used for reverse transcription
(RT), after treatment with RQ1 DNAse (Promega). RT was per-
formed using AMV reverse transcriptase (Promega) and random
primers (Promega). Following incubation for 10 min at room tem-
perature, the following RT program was used: 42C for 1 hr and
99C for 5 min, before cooling to 4C using a PCR Sprint Thermo
Cycler (Thermo Electron Corporation, Basingstoke, UK).
Real time PCR
Real-time polymerase chain reaction (PCR) was performed
using an ABI 7900HT Fast Real-Time PCR System (Applied Bio-
systems, Warrington, UK). Eukaryotic 18S rRNA endogenous
control (VIC/TAMRA probe, primer limited) and TaqMan Gene
Expression Assays were purchased from Applied Biosystems. The
following TaqMan Gene Expression Assays were used:
 HIF-1a, assay id: Hs00153153_m1
 Carbonic anhydrase IX (CAIX), assay id: Hs00154208_m1
 Lysyl oxidase (LOX), assay id: Hs00184700_m1
Ten microlitre real-time PCR reactions were set up in 384-well
plates and consisted of 5 ll TaqMan Universal PCR Master Mix
(Applied Biosystems), 0.5 ll TaqMan gene expression assays and
4.5 ll sample cDNA. Each PCR reaction contained 6.5 ng of
reverse transcribed RNA in 10 ll. Only DNA samples with an 18S
cycle threshold (CT) value of <23 were used for analysis as this
value suggesting the RNA was of sufﬁcient quality for analysis of
gene expression. The relative standard curve method was used to
determine the fold change in gene expression between treated and
untreated cells.
HIF-1a RNA interference
PC-3 cells were plated out in a 6-well plate (1 3 105 cells/
well) using RPMI-1640 without antibiotics. Twenty-four hours
after plating, the PC-3 cells were transfected with 40 nM
Stealth RNAi speciﬁc to HIF-1a or 40 nM Stealth RNAi Nega-
tive Control using Lipofectamine 2000 with Opti-MEM reduced
serum medium as a dilutant (all Invitrogen). Transfected cells
were incubated under normoxic incubator conditions for 24 hr
following transfection before NO-sulindac treatment and
hypoxic incubation. After a further 48 hr, the effect of HIF-1a
RNAi on cell survival was determined using PI staining and
ﬂow cytometric analysis. At the same time point, an assessment
of HIF-1a knockdown was made using immunoblotting. Trans-
fection efﬁciency was assessed by transfection with 100 nM
BLOCK-iT Fluorescent Oligo (Invitrogen) and subsequent visu-
alization of cells by ﬂuorescent microscopy.
Statistical analysis
Each experiment was repeated in triplicate at least 3 times. All
values are expressed as mean 6 standard error (SEM). Mean val-
ues were compared using the Mann-Whitney U test. p < 0.05 was
considered to be signiﬁcant.
Results
NO-sulindac causes PC-3 prostate cancer cell death in
a dose- and time-dependent fashion
Figure 2a illustrates that PC-3 cell death, caused by NO-sulin-
dac, increased in a time-of-exposure and dose-dependent fashion.
NO-sulindac was signiﬁcantly more cytotoxic at all doses (10–100
lM) than unnitrated sulindac (p < 0.02, Mann-Whitney U test).
Based on these dose response experiments and previous studies
involving sulindac,32 25 and 50 lM of NO-sulindac or sulindac
were chosen for use in subsequent experiments.
The sulindac/linker and NO-releasing subunits are responsible
for the cytotoxic effect of NO-sulindac
Experiments were performed to determine the role of each sub-
unit of NO-sulindac (sulindac, linker/spacer and NO-releasing
group; Fig. 1) in the cytotoxic effect of NO-sulindac. After 48 hr
exposure of PC-3 cell to DMSO or sulindac under normoxia, the
nitrite concentration, used as estimate of nitric oxide production,
was below the limits of detection of the Griess assay (Fig. 2b).
Furthermore, the nitrite concentration following treatment of PC-3
cells at both 25 lM and 50 lM NO-sulindac for 48 hr was measur-
able but low (<2 lM). The nitrite concentration of sodium nitro-
prusside (SNP) combined in equimolar amounts with sulindac was
20- to 32-fold greater than that of NO-sulindac. Despite this ﬁnd-
ing, the combined sulindac 1 SNP treatment did not match the cy-
totoxic effect of NO-sulindac and was not signiﬁcantly more cyto-
toxic than DMSO control treated cells (Fig. 2b). However, treat-
ment of PC-3 cells for 48 hr with the denitrated analogue of NO-
sulindac, NCX 221 (composed of sulindac and the linker), resulted
in a signiﬁcant reduction in cell survival relative to control treated
cells, but did not reduce cell survival to the same extent as NO-
sulindac (Fig. 2b). These results suggest that the linker/spacer of
NO-sulindac is partly responsible for the cytotoxic effects
observed earlier.
Effect of hypoxia on the cytotoxic effect of NO-sulindac
PC-3 cells were incubated at several different oxygen levels
(0.2, 5, 10 and 21% oxygen) to assess the effect of hypoxia on cell
growth and cytotoxic effects of NO-sulindac. Figures 2c and 2d
show the relative survival of PC-3 cells incubated at differing oxy-
gen levels and treated with 25 lM and 50 lM sulindac or NO-
sulindac, compared to DMSO vehicle control.
As the cell incubation oxygen level was reduced, the relative sur-
vival of PC-3 cells also serially declined (Figs. 2c and 2d). PC-3
cells treated with the DMSO vehicle control incubated at 21% oxy-
gen had a signiﬁcantly higher relative survival than PC-3 cells incu-
bated at 10, 5 or 0.2% oxygen (p< 0.005, Mann-Whitney U test).
At all oxygen levels used, treatment of PC-3 cells with either 25
lM or 50 lM NO-sulindac resulted in a signiﬁcant reduction in
relative survival compared with the DMSO vehicle control at the
same oxygen level (Fig. 2c). Conversely, treatment of the PC-3
cells with 25 lM or 50 lM sulindac did not result in a signiﬁcant
difference in relative survival compared to the control, at any oxy-
gen level utilised. At each oxygen level, NO-sulindac was signiﬁ-
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cantly more cytotoxic than sulindac (p < 0.04, Mann-Whitney U
test). However, at both the 25 lM and 50 lM doses of NO-sulin-
dac, there appeared to be a reduction in cell death and a relative
increase in survival as the oxygen level was reduced.
NO-sulindac treatment but not hypoxia alone alters
the PC-3 cell cycle
Cell cycle analysis was performed to determine if hypoxia
altered the cell cycle of PC-3 cells and was potentially responsible
for the reduced cytotoxic effect of NO-sulindac under hypoxia.
Figure 3a illustrates that incubation of PC-3 cells under hypoxia
and/or treatment with 25 lM sulindac for 48 hr did not alter the
cell cycle other than a doubling of cells at the sub-G1 phase found
under normoxia. However, when the cells were treated for 48 hr
with 25 lM NO-sulindac under both normoxia and hypoxia there
was an alteration in the cell cycle. At 21% and 0.2% oxygen lev-
els, NO-sulindac resulted in 20.4% and 18.5% apoptosis (sub-G1),
respectively, with a corresponding reduction in cells in G0/G1.
Following treatment with NO-sulindac there was an increase in
cells in G2/M from 33.3 to 50.4% at normoxia and from 39.9 to
56.1% under hypoxia.
NO-sulindac inhibits the invasion of PC-3 cells under
normoxia and hypoxia
Figures 3b and 3c illustrates that NO-sulindac treated PC-3 cells,
under both normoxia and hypoxia, underwent a signiﬁcantly lower
level of cell invasion than either sulindac or control treated cells.
Following exposure of normoxic PC-3 cells to 25 lM NO-sulin-
dac for 24 hr, 24% cells were killed relative to DMSO vehicle
control (Fig. 2a). Under the same conditions, 41% of PC-3 cells
invaded through the Matrigel of the tumour invasion system. As
such, of the 59% PC-3 cells not undergoing invasion, following
NO-sulindac treatment, 24% may be due to cell death but at least
35% cells were alive but prevented from invading by NO-sulindac
treatment.
NO-sulindac reduces nuclear HIF-1a protein expression
Figures 4a and 4b show western blots for HIF-1a at 4 different
oxygen levels. Figure 4 shows that HIF-1a was not upregulated at
10 or 5% oxygen level compared to PC-3 cells incubated at 21% ox-
ygen. However, at 0.2% oxygen there was increased HIF-1a in the
nucleus. At each of the hypoxic oxygen levels, there was a downre-
gulation of HIF-1a expression on treatment with NO-sulindac. The
greatest reduction in HIF-1a was at the 0.2% oxygen level com-
pared to the control treated cells. Figure 4b illustrates an increase in
the level of HIF-1a protein stabilization following sulindac treat-
ment of the PC-3 cells at the 4 different oxygen levels. Immunocyto-
chemistry (Fig. 5a) also demonstrated that under hypoxia there was
an increase in HIF-1a translocation to the nucleoplasm, but not the
nucleolus. NO-sulindac reduced nuclear translocation of HIF-1a in
hypoxic PC-3 cells.
NO-sulindac downregulates activation of the hypoxia response
element promoter region
PC-3 cells transiently transfected with a luciferase gene under
the control of the hypoxia response element (HRE) were
employed to evaluate the consequences of NO-sulindac treatment
on HIF-1a transcriptional activity. Figure 5b illustrates a 5.3-fold
increase in HRE promoter activation following incubation at 0.2%
oxygen compared to 21% oxygen. Treatment with 25 lM NO-
FIGURE 2 – Cytotoxic effect of NO-sulindac under varying oxygen
conditions. A determination of the cytotoxic effect of NO-sulindac and
its derivatives on PC-3 cells was made using PI uptake and ﬂow cyto-
metric analysis. (a) The effect of differing doses of NO-sulindac and
sulindac on normoxic PC-3 cells, relative to DMSO vehicle control
treated cells. (b) Bar graph showing the differing cytotoxic effects and
nitrite concentrations of 25–50 lM: sulindac, combined sulindac 1
SNP (established NO-donor), NCX 221 (denitrated analogue of NO-
sulindac) and NO-sulindac on PC-3 cells after 48 hr incubation at nor-
moxia. Nitrite concentrations of PC-3 cell medium, measured using
the Griess assay, following each treatment are documented above the
corresponding graph bar. Differences in cell survival between NO-
sulindac and NCX 221 treated cells are shown as, *p < 0.005. (c) The
effect of NO-sulindac or (d) sulindac on PC-3 cells incubated for 48 hr
under differing oxygen conditions. Survival expressed relative to PC-3
cells treated with the DMSO vehicle control at 21% oxygen. Differen-
ces from control at the same oxygen level are shown as, a: p < 0.05,
b: p < 0.005, c: p < 0.0005, Mann-Whitney U test. There was no sig-
niﬁcant difference between the relative survival of sulindac treated
PC-3 cells and control treated cells at any oxygen level.
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sulindac at 0.2% oxygen resulted in a 31.2% relative reduction in
HRE promoter activation compared to the DMSO control (p 5
0.028, Mann-Whitney U test). Whereas, treatment with 25 lM
sulindac resulted in a 5.2% increase in HRE promoter activation.
NO-sulindac reduces the mRNA expression of selected
hypoxia associated genes
Table I details the fold-change in selected hypoxia associated
gene expression following PC-3 cell incubation at 0.2% oxygen.
LOX and CAIX were upregulated 2.3- and 6.1-fold respectively
following incubation of PC-3 cells at 0.2% oxygen compared to
21% oxygen incubation. HIF-1a mRNA expression by hypoxic
PC-3 cells was downregulated to 0.6-fold of the level found under
normoxia.
LOX and CAIX mRNA expression showed the same pattern
found with the HIF-1a protein and HRE promoter reporter con-
struct following the treatment of PC-3 cells with sulindac or NO-
sulindac (Table I). PC-3 cell treatment with 25 lM or 50 lM NO-
sulindac under 0.2% oxygen conditions resulted in a reduction in
LOX and CAIX mRNA. There was also a reduction in LOX
mRNA expression following sulindac treatment; however, this
was not as great a reduction as with NO-sulindac. CAIX gene
expression was reduced by the 50 lM sulindac used but slightly
increased by 25 lM sulindac. HIF-1a mRNA expression was
reduced by 50 lM NO-sulindac and both doses of sulindac used.
As such, HIF-1a did not show a well-deﬁned alteration in the pat-
tern of mRNA expression and did not exhibit the same downregu-
lation observed in HIF-1a at the protein level.
Reduction of HIF-1a expression is partially responsible
for the hypoxia induced resistance of PC-3 cells to NO-sulindac
After incubating for 48 hr under both normoxia and hypoxia,
the relative survival of control treated PC-3 cells transfected with
HIF-1a RNAi was signiﬁcantly lower than cells transfected with
the negative control RNAi (Fig. 5c). NO-sulindac treatment of
HIF-1a RNAi transfected, normoxic PC-3 cells did not result in
an increase in cell death over negative control transfected cells.
However, under hypoxic conditions there was a signiﬁcant reduc-
FIGURE 3 – (a) Effect of hypoxia, NO-sulindac and sulindac on cell
cycle progression of PC-3 cells. PC-3 cells were incubated for 48 hr at
21% or 0.2% oxygen with the following additives: nil, 25 lM NO-
sulindac, 25 lM sulindac. PC-3 cells were analysed for PI stained
DNA content by ﬂow cytometry. Values represent the percentage of
cells at each point of the cell cycle. (b) and (c) Effect of hypoxia, NO-
sulindac and sulindac on cell invasion of PC-3 cells. PC-3 cells were
incubated with 25 lM NO-sulindac, 25 lM sulindac or 0.05% DMSO
for 48 hr under either (b) normoxia or (c) hypoxia on a BD BioCoatTM
Tumor invasion system to assess the effect on cell invasion. Differen-
ces from sulindac or DMSO control indicated as, a: p < 0.03, b: p <
0.05, Mann-Whitney U test.
FIGURE 4 – NO-sulindac treatment reduces the level of HIF-1a nu-
clear protein in hypoxic PC-3 cells. Nuclear protein extracts were iso-
lated from PC-3 cells incubated at 4 different oxygen levels and
treated with sulindac, NO-sulindac or the DMSO vehicle control.
Cobalt chloride (CoCl2, a hypoxia mimicking agent) treated cells
acted as the positive control for HIF-1a western blot. (a) Radiograph
of HIF-1a (120 kDa) and b actin (42 kDa) western blot of nuclear pro-
tein extract from PC-3 cells treated with 100 lM CoCl2 or 0.1%
DMSO at 21% oxygen. Note that PC-3 cells expressed HIF-1a under
normoxia, an unusual characteristic which has been noted previ-
ously.33 (b) Radiograph of HIF-1a and b actin western blot of nuclear
protein extract from PC-3 cells treated with 50 lM NO-sulindac
(NCX), 50 lM sulindac (NSAID) or 0.1% DMSO-vehicle control
incubated at 0.2% to 10% oxygen levels for 48 hr.
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tion in HIF-1a RNAi transfected PC-3 cell survival following
NO-sulindac treatment compared to negative control transfected
cells. Under these conditions, cell survival was reduced to the
same level as following 25 lM NO-sulindac treatment under nor-
moxic conditions (p 5 0.2, Mann-Whitney U test), i.e., hypoxia
induced chemoresistance was overcome.
Inhibition of HIF-1a accumulation by NO-sulindac
in PC-3 cells is independent of proteasomal degradation
Under normoxia HIF-1a is normally degraded by ubiquitination
and subsequent proteolysis within the proteasome. The hypothesis
that the HIF-1a degradation induced by NO-sulindac was due to
promotion of the proteasome pathway was tested by pre-treating
FIGURE 5 – (a) NO-sulindac reduces nuclear translocation of HIF-1a. PC-3 cells were incubated for 48 hr under normoxia or hypoxia with or
without 25 lM NO-sulindac. The subcellular localization of HIF-1a (FITC) and of the nucleolar marker ﬁbrillarin (Texas red) was then assessed
by immunocytochemical staining. The merged panel is a pseudocolour image generated by combining the FITC (green), Texas red (red), and
DAPI (blue) channels. Cytoplasmic HIF-1a staining was present in PC-3 cells under normoxia and hypoxia, which has been noted in previous
studies.33 Nuclear HIF-1a staining occurred following hypoxic incubation. Treatment of the PC-3 cells with 25 lM NO-sulindac resulted in a
reduced intensity of HIF-1a staining under hypoxia. Magniﬁcation 31,000. (b) Graph showing luciferase activity of PC-3 cells co-transfected
with the pGL2-Tk-HRE and b-galactosidase plasmids. Transfected cells were treated for 48 hr with 25 lM sulindac or 25 lM NO-sulindac and
incubated under normoxia or hypoxia (0.2% oxygen). Results expressed as luciferase units per b-galactosidase unit, relative to the background
expression levels of untransfected cells. Signiﬁcant differences from the ‘‘transfected 1 nil’’ PC-3 cells incubated at 0.2% oxygen are shown as,
a: p < 0.03, Mann-Whitney U test. (c) The effect of HIF-1a RNAi on hypoxic PC-3 cells. Radiograph of HIF-1a (120 kDa) and b actin (42 kDa)
Western blot of nuclear protein extract from PC-3 cells transfected with 2 different HIF-1a RNAi oligomers and a negative control oligomer and
incubated at 0.2% oxygen for 48 hr, 1 day following cell transfection. Both HIF-1a RNAi oligomers resulted in reduced levels of HIF-1a produc-
tion compared with the negative control oligomer. HIF-1a RNAi oligomer 1 produced the greatest HIF-1a knockdown and was used for cell sur-
vival experiments. Transfection of PC-3 cells with the BLOCK-iT Fluorescent Oligo showed 70% transfection efﬁciency (data not shown). The
effect of HIF-1a expression on PC-3 cell survival following exposure to normoxia/hypoxia and DMSO/NO-sulindac is shown relative to DMSO
control treated cells under normoxia. HIF-1a RNAi caused a reduction in cell survival under both normoxia/DMSO and hypoxia/DMSO condi-
tions. HIF-1a RNAi caused a further fall in cell survival in PC-3 cells treated with NO-sulindac under hypoxia but not normoxia.
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PC-3 cells with the proteasome inhibitor MG132 whilst co-admin-
istering NO-sulindac and incubating under hypoxic conditions.
Pre-treatment of normoxic PC-3 cells with MG132 upregulated
HIF-1a expression (Fig. 6a). However, the inhibition by NO-
sulindac of HIF-1a accumulation in response to hypoxia was not
blocked by MG132. As such, the inhibition of HIF-1a by NO-
sulindac was not due to proteasomal degradation.
NO-sulindac inhibits HIF-1a via the PI3K/Akt pathway
under hypoxia
Treatment of hypoxic PC-3 cells with the PI3K inhibitor
LY294002 caused a dose-dependent reduction in phosphorylation
of Akt at serine 473 (Fig. 6b). Under the same conditions, nuclear
HIF-1a levels were also reduced suggesting a link between the
PI3K/Akt pathway and HIF-1a stabilization. Similarly, on treat-
ment of PC-3 cells with 25 lM NO-sulindac p-Akt levels were
suppressed in tandem with HIF-1a expression (Fig. 6c), showing
that NO-sulindac may exert its effects under hypoxia via Akt. Co-
transfection of PC-3 cells with pGL2-Tk-HRE and myr-Akt
restored the NO-sulindac inhibited HRE-promoter reporter activ-
ity, in a dose-dependent fashion (Fig. 6d). Control treated myr-Akt
transfected cells demonstrated a 1.8-fold increase in HRE pro-
moter reporter activation by HIF-1a which was unchanged by 5
lM NO-sulindac and not reduced to the same level as sham trans-
fected cells by higher doses of NO-sulindac. This ﬁnding illus-
trated that Akt was involved in NO-sulindac mediated HIF-1a
inhibition.
Discussion
The data presented earlier illustrates novel tumouricidal and
anti-invasion properties of NO-sulindac in a hypoxic microenvi-
ronment. Under low oxygen conditions, NO-sulindac directly
inhibited the hypoxia response of hormone-resistant PC-3 prostate
cancer cells in vitro via Akt signalling. NO-sulindac was cytotoxic
in a dose- and time-of-exposure-dependent fashion.
Previous work from our laboratory determined that NO-aspirin
and NO-ibuprofen inhibited proliferation and induced apoptosis in
a dose-dependent fashion in PC-3, LNCaP and prostatic stromal
cells.34 NO-aspirin and NO-ibuprofen were both more effective at
inhibiting proliferation and inducing apoptosis than conventional
FIGURE 6 – (a) The role of the proteasome in degradation of HIF-1a. PC-3 cells were treated for 4 hr under normoxic or hypoxic conditions
with proteasome inhibitor MG132 (10 lM) and for 48 hr with 50 lM NO-sulindac before immunoblotting. Proteasome inhibition with MG132
caused an accumulation of HIF-1a. NO-sulindac treatment resulted in a reduction in nuclear HIF-1a protein; however, the co-administration of
MG132 with NO-sulindac did not alter HIF-1a levels. (b, c) NO-sulindac induced inhibition of HIF-1a via the Akt pathway under hypoxia. PC-
3 cells were incubated with the PI3K inhibitor LY294002 under hypoxic conditions for 48 hr. Western blot analysis revealed a dose dependent,
concurrent reduction in p-Akt (65 kDa) and HIF-1a following LY294002 treatment. (c) Before immunoblotting for p-Akt and HIF-1a, PC-3
cells were pretreated with 0.05% DMSO or 25 lM NO-sulindac followed by hypoxic incubation for 48 hr. HIF-1a and P-Akt protein levels
were both reduced following NO-sulindac treatment. (d) PC-3 cells cotransfected with pGL2-Tk-HRE and myr-Akt [or empty vector pUSEamp
(ev)] plasmids were treated with 0.05% DMSO or 5–25 lM NO-sulindac for 48 hr under hypoxic conditions. Transfection of PC-3 cells with
myr-Akt prevented the reduction in activation of the HRE following NO-sulindac treatment, in a dose-dependent fashion. Data represents the
fold increase in luciferase expression relative to that of the empty vector control in the presence of DMSO. Increased p-Akt protein levels fol-
lowing transfection were determined by immunoblot.
TABLE I – REAL-TIME PCR QUANTIFICATION OF THE FOLD-CHANGE OF
HYPOXIA-ASSOCIATED GENE EXPRESSION IN (i) UNTREATED PC-3 CELLS
INCUBATED AT 0.2% OXYGEN (RELATIVE TO GENE EXPRESSION AT 21%
OXYGEN) AND (ii) HYPOXIC PC-3 CELLS TREATED WITH SULINDAC OR
NO-SULINDAC (RELATIVE TO GENE EXPRESSION IN HYPOXIC/DMSO
VEHICLE CONTROL TREATED CELLS). RESULTS EXPRESSED AS FOLD
CHANGE 6SD
HIF-1a CAIX LOX
(i) Oxygen treatment
0.2% oxygen 0.59 6 0.26 6.07 6 1.72 2.37 6 0.77
(ii) Drug treatment
NO-sulindac 25 lM 1.11 6 0.35 0.78 6 0.05 0.13 6 0.19
NO-sulindac 50 lM 0.51 6 0.11 0.37 6 0.07 0.24 6 0.09
Sulindac 25 lM 0.84 6 0.63 1.15 6 0.22 0.65 6 0.17
Sulindac 50 lM 0.53 6 0.12 0.64 6 0.08 0.62 6 0.16
SD, standard deviation.
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aspirin, ibuprofen or the NO-donor SNP. Previous studies using
NO-sulindac demonstrated a cytotoxic and antiproliferative effect
on normoxic LNCaP and PC-3 cell lines.35,36 In these previous
studies by Huguenin et al.,36 NO-sulindac was also found to alter
the cell cycle, induce mitotic arrest and display pro-apoptotic ac-
tivity in malignant and benign cell lines. The results of the nor-
moxia experiments in the present study concur with these previous
results showing a reduction in PC-3 cell viability in a dose- and
time-dependent manner following treatment with NO-sulindac as
well as a comparable rate of apoptosis.
Recent studies, from several research groups, have established
that the cytotoxic activity of NO-aspirin has little or nothing to do
with the NO-releasing or aspirin groups and that the linker/spacer
is biologically active.37–40 As such, we assessed the cytotoxic
effect and NO-releasing properties of the various components of
the NO-sulindac compound. Previous studies have suggested that
the anti-tumour effect of NO-aspirin involves a quinone methide
(formed from the hydroxybenzyl linker) but neither nitric oxide
nor aspirin.38,40 However, this expectation does not extend to
other linker structures40; the spacer found in NO-sulindac is a
butyloxy linker which does not form a quinone. In vivo and in
vitro, unlike NO-aspirin, NO-sulindac is predicted to function as a
NO-donor and deliver ‘NO• bioactivity (personal communication,
Professor Gregory Thatcher (University of Illinois, Chicago).
However, such effects are likely to be reduced in cell culture as
nitrates require metabolic bioactivation to liberate NO• bioactiv-
ity, which is often poorly replicated in vitro.40 The low levels of
nitrite released by NO-sulindac concur with these predictions, it
may be that the NO• release would be higher in vivo. In the pres-
ent study, despite releasing a much higher concentration of NO•,
the combination of SNP 1 sulindac was signiﬁcantly less cyto-
toxic than NO-sulindac. The denitrated analogue of NO-sulindac
(i.e., sulindac 1 spacer) had an intermediate cytotoxic effect,
greater than DMSO vehicle control but lower than NO-sulindac.
Taken together, these ﬁndings suggest that the spacer of NO-sulin-
dac is not inert and that the NO-releasing group provided some of
the cytotoxic effect of NO-sulindac (unlike NO-aspirin where the
NO-releasing moiety does not appear to be needed37). It remains
to be determined if the sulindac moiety is required in combination
with both the linker and NO-releasing group to achieve the same
biological activity.
It is well established that solid human tumours exist under
hypoxic conditions and that this is the case within a nidus of pros-
tate cancer.18,19 Hypoxia is known to increase the resistance of
tumours to chemotherapeutic drugs.20 As such, it was important to
establish the cytotoxic effects of NO-sulindac under hypoxia.
Oxygen levels of less than 1% O2 (pO2 10 mmHg) characterize
tissues which have compromised blood ﬂow such as prostate can-
cer which have been demonstrated to have an average median pO2
of 2.4 mmHg.18,41 As such, 0.2% oxygen was used in the experi-
ments of the present study to mimic the median pO2 in vivo. This
choice was ratiﬁed by the consistent upregulation of HIF-1a, as a
surrogate for induction of the hypoxia response, at 0.2% oxygen
but neither 5 nor 10% oxygen. The results from the current study
showed that as the oxygen levels fell, the relative survival of PC-3
cells decreased to 75% viability at 10% oxygen, 68% at 5% oxy-
gen and 62% at 0.2% oxygen. Although atmospheric oxygen con-
centration is 21%, the level of oxygen in tissues in vivo is signiﬁ-
cantly lower (physiological hypoxia) with a mean tissue oxygen
concentration 3%.42 Thus, incubation of PC-3 cells at 5% and
10% oxygen was likely to represent physiological rather than patho-
logical oxygen levels. These in vitro ﬁndings suggest that such phys-
iological hypoxia resulted in PC-3 cell death perhaps reﬂects the
difﬁculty in attempting physiological studies in tissue culture.
Treatment of PC-3 cells with 25 lM or 50 lM of NO-sulindac
at the 4 different oxygen levels resulted in a signiﬁcant increase in
cell death relative to the control. However, a degree of chemore-
sistance was introduced by hypoxia. At both 25 lM and 50 lM
doses of NO-sulindac, cell killing was greatest at 21% oxygen. As
the oxygen level was reduced there was an increase in the relative
PC-3 cell survival. However, at both doses of NO-sulindac (but
not sulindac) used there was still a signiﬁcant reduction in survival
relative to the PC-3 cells treated with the vehicle control. Other
than a doubling of the proportion of cells undergoing apoptosis
under hypoxia (but only from 0.8 to 1.7%) there were no major
cell cycle differences between hypoxic and normoxic PC-3 cells.
As such, a slowing of the cell cycle in hypoxic cells was not re-
sponsible for the reduced effect of NO-sulindac on hypoxic PC-3
cells. A previous study demonstrated that hypoxia-induced resist-
ance to cisplatin and doxorubicin in non-small cell lung cancer
was inhibited by silencing of HIF-1a mRNA.43 Similarly, in the
present study, knockdown of HIF-1a mRNA combined with NO-
sulindac treatment reversed the chemoresistance induced by
hypoxia, suggesting that HIF-1a expression under hypoxia may
be responsible for hypoxia induced chemoresistance. However,
despite chemoresistance these results demonstrate that overall
NO-sulindac has signiﬁcant cytotoxic effects under hypoxia.
Hypoxia is associated with increased invasive and metastatic
potential. Previous studies have shown that the increased metasta-
sis induced by hypoxia was inhibited in murine melanoma cells by
co-incubation with low concentrations of the NO-mimetic drugs
glyceryl trinitrate and diethylenetriamine NO• adduct (DETA/
NO).44 The signiﬁcant reduction in PC-3 cell invasion caused by
NO-sulindac under normoxia and hypoxia suggests that NO-sulin-
dac may also act to prevent invasion and metastasis of prostate
cancer cells in vivo.
The immunoblot, immunocytochemical and HRE promoter re-
porter construct data conﬁrm that the HIF-1a protein and its tran-
scriptional activity were inhibited by NO-sulindac under normoxic
and hypoxic conditions by up to 31%. Quantitative real-time PCR
was performed to assess the effect that NO-sulindac treatment of
PC-3 cells had on a number of hypoxia-associated genes. As
expected, mRNA of the hypoxia-associated genes: CAIX and
LOX were upregulated in PC-3 cells following hypoxic incuba-
tion. LOX and CAIX mRNA levels were downregulated by treat-
ment of hypoxic PC-3 cells with NO-sulindac. Unlike the HIF-1a
protein levels and HRE promoter construct results, unnitrated
sulindac also reduced the LOX and CAIX mRNA levels but not to
the extent of NO-sulindac. As shown in previous studies HIF-1a
mRNA levels were neither upregulated under hypoxia45–47 nor
was HIF-1a mRNA downregulated by NO-sulindac treatment.
Overall, the results obtained in these experiments suggest that
NO-sulindac causes the downregulation of HIF-1a protein stabi-
lization production and also reduces the usual upregulation of
hypoxia-associated genes occurring under hypoxia. These ﬁnd-
ings concur with a recent study by Rigas and coworkers,48 dem-
onstrating that NO-aspirin inhibits angiogenesis by suppressing
VEGF expression in human colon cancer mouse xenografts. Fur-
thermore, previous studies have shown that the 2 subunits of
NO-NSAIDs, NO• and NSAIDs, can reduce HIF levels inde-
pendently.49–51 Inhibition of the hypoxia response may allow
modulation of the invasion (demonstrated earlier) and metastasis
of hypoxic prostate cancer cells, reduction in the resistance of
tumour cells to chemotherapy and reduced mortality of HIF-1
expressing tumours.
The results of experiments with the proteasome inhibitor
MG132 show that NO-sulindac induced reduction in HIF-1a
levels was not due to the proteasomal activity responsible for
HIF-1a degradation under normoxic conditions. These results
taken together with the real-time PCR ﬁndings that HIF-1a
mRNA levels were not reduced by the combination of hypoxia
and NO-sulindac suggest a potential downregulation of HIF-1a
mRNA translation rather than transcription. Previous studies
have also proposed that HIF-1a expression is mainly regulated
at a post-transcriptional rather than at a transcriptional level.47,52
Regulation of HIF-1a expression at the translational step during
hypoxia is essential as HIF-1a mRNA translation must circum-
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vent the general reduction in translation rates that occur under
hypoxic conditions.46
A number of previous studies have demonstrated the link
between the PI3K-Akt-mTOR signal transduction pathway and
control of HIF-1a expression under hypoxia.46,53,54 As such, the
effect of NO-sulindac on this axis was investigated further. The
present study demonstrated that HIF-1a nuclear protein levels
were reduced in parallel with phosphorylation of Akt by both
PI3K inhibitor (LY294002) and NO-sulindac. Experiments using
PC-3 cells co-transfected with the HRE promoter reporter and
constitutively expressing Akt plasmids linked Akt phosphorylation
to HIF-1a production by PC-3 cells under hypoxia, suggesting
that this is one mechanism by which NO-sulindac functions. Other
HIF-1a inhibitors, such as YC-1, also regulate HIF-1a translation
via the PI3K-Akt-mTOR signal transduction pathway.46 Clearly,
there may be other mechanisms at play in the regulation of HIF-
1a by NO-sulindac.
A notable ﬁnding of this study was that while the relative
amount of cell death caused by NO-sulindac fell with diminishing
oxygen levels, HIF-1a protein accumulation was also reduced.
This raises the question of why under hypoxia, cell death due to
NO-sulindac was not greater, as NO-sulindac caused a reduction
in hypoxia-associated proteins, potentially preventing adaption of
the hypoxic cells to the harsh microenvironment. Intuitively, HIF-
1a levels would be expected to be inversely proportional to the
level of cytotoxicity observed under hypoxic conditions. Further-
more, results of RNAi experiments showed that, under hypoxia,
knock-down of HIF-1a alone caused a greater reduction in PC-3
cell survival than NO-sulindac treatment. However, HIF-1a pro-
tein was reduced to a lesser degree (20–30% reduction) by 25–
50 lM NO-sulindac than by RNAi, suggesting that although the
reduction in HIF-1a by NO-sulindac may be partly responsible for
its cell death induction it was not the sole reason. Additionally,
similar studies evaluating the HIF-1a inhibitor YC-1 showed that
the inhibition of HIF-1a accumulation by YC-1 under hypoxia
was not attributable to cell death.46
This study determined for the ﬁrst time that NO-sulindac is sig-
niﬁcantly more active than sulindac as a cytotoxic, anti-invasion
agent against the PC-3 hormone-insensitive prostate cancer cell
line under hypoxia. NO-sulindac directly inhibits the HIF-1a
induced hypoxia response via the inhibition of Akt translation
upregulation. The ability of NO-sulindac to inhibit tumour adap-
tion to hypoxia potentially has far-reaching implications and is of
considerable relevance to the future management of hormone-
insensitive prostate cancer with the same cellular characteristics as
PC-3 cells. In vivo conﬁrmation of the results from this study is
now required. However, combination of pre-clinical evidence data
presented here and elsewhere, epidemiological evidence of the
role of NSAIDs in prostate cancer prevention and gastroprotective
beneﬁt of NO-NSAIDs suggest that NO-sulindac is potentially a
useful agent for the future treatment of prostate cancer.
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